Bruce Booth

Bruce Booth is a partner at Atlas Venture, focused on the discovery and development of novel medicines and therapeutic platforms.

Bruce is currently chairman of Arkuda Therapeutics, AvroBio (NASDAQ:AVRO), Hotspot Therapeutics, Kymera Therapeutics (NASDAQ:KYMR), Nimbus Therapeutics, and Quench Bio. He also serves on the board of Magenta Therapeutics (NASDAQ:MGTA) and several seed stage companies. He previously served on the boards of past Atlas companies Avila (acquired by Celgene), Lysosomal Therapeutics, miRagen (NASDAQ:MGEN), Padlock (acquired by BMS), Prestwick (acquired by Biovail), Rodin Therapeutics (acquired by Alkermes), Stromedix (acquired by Biogen), Unum Therapeutics (NASDAQ:UMRX), and a number of other ventures.

Bruce serves or has served as an advisor in various capacities to Takeda, UCB, and the Gates Foundation. He also serves on the boards of the Pennsylvania State Research Foundation, which helps with technology transfer for Penn State, and New England Disabled Sports, a charity dedicated to adaptive sports. Bruce blogs about biotech and venture capital topics at LifeSciVC.com, which is syndicated on Forbes.

Prior to joining Atlas in 2005, Bruce was a consultant at McKinsey & Company, as well as an investor for Caxton Health Holdings. As a British Marshall Scholar, Bruce received a D.Phil. (PhD) in molecular immunology from Oxford University. He received a BS in biochemistry, summa cum laude, from The Pennsylvania State University.

Bruce enjoys running, skiing, hiking, and fly fishing. He lives in Wellesley, MA and has three wonderful kids.